Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
Urogen Pharma (URGN) Stock Price & Analysis
427 Followers
URGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.69 - $24.13
Previous Close$16.93
Volume625.64K
Average Volume (3M)620.25K
Market Cap
$697.01M
Enterprise Value$631.19M
Total Cash (Recent Filing)$164.04M
Total Debt (Recent Filing)$98.23M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 08, 2024EPS Estimate
-$0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.39
Shares Outstanding36,130,121
10 Day Avg. Volume1,934,109
30 Day Avg. Volume620,252
Standard Deviation0.24
R-Squared0.06
Alpha-0.00523
Financial Highlights & Ratios
Price to Book (P/B)-9.15
Price to Sales (P/S)31.76
Price to Cash Flow (P/CF)-11.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.49
Enterprise Value/Gross Profit8.60
Enterprise Value/Ebitda-10.28
Forecast
1Y Price Target
$55.50Price Target Upside209.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Urogen Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical DataEncouraging data for UGN-102 exceeded expectations on 12-month durability of response.
Financial PerformanceEquity financing completed—cash runway extended, potentially through to break-even.
LeadershipUroGen announced the appointment of a new Chief Commercial Officer, David Lin, who possesses significant pharmaceutical industry experience.
Bears Say
Financial PerformanceQ1 Jelmyto net revenue of $18.8MM was below consensus and estimates, partially due to discounts related to Medicare refunds for discarded drugs.
Product PerformanceProduct revenue of $18.8 million came in below estimates.
Sales DeclineThe company attributed the 20% sequential decline in sales to seasonal insurance reimbursement wrinkles.
---
Ownership Overview
9.00% Insiders
2.54% Mutual Funds
50.18% Other Institutional Investors
38.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $8.69 and its highest was $24.13 in the past 12 months.
What is Urogen Pharma’s market cap?
Currently, no data Available
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Aug 08, 2024 which is in 18 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on May 13, 2024. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.867 by -$0.103.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -$0.84.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 41,169,952 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.867. Following the earnings report the stock price went up 2.59%.
Which hedge fund is a major shareholder of Urogen Pharma?
Among the largest hedge funds holding Urogen Pharma’s share is RA Capital Management. It holds Urogen Pharma’s shares valued at 46M.
---
Urogen Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.50 (209.71% Upside)
$55.50 (209.71% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 15.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.57%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in New York, NY.
---
URGN Earnings Call
Q1 2024
0:00 / 0:00
---
URGN Stock 12 Month Forecast
Average Price Target
$55.50
▲(209.71% Upside)
Technical Analysis
Best Analysts Covering URGN
1 Year
1 Year Success Rate
13/16 ratings generated profit
1 Year Average Return
+29.31%
reiterated a buy rating 21 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +29.31% per trade.
---